Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.44 |
| ▸ | YAP1 | P46937 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607180 | 0.90 | MEN1 (0.46) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL6083618 | 0.89 | EGLN2 (0.50) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL605683 | 0.89 | MEN1 (0.46) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL17609000 | 0.89 | OPRD1 (0.47) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL607947 | 0.89 | TACR1 (0.47) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL16825735 | 0.88 | MEN1 (0.45) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL16825914 | 0.87 | OPRD1 (0.45) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL24940830 | 0.86 | MEN1 (0.43) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL17608882 | 0.86 | P2RX7 (0.44) | OPRD1OPRK1MEN1KMT2ATACR1 | |
| SCHEMBL551650 | 0.86 | MEN1 (0.48) | OPRD1OPRK1MEN1KMT2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| EP-2164829-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150089-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | OPRD1 4455/4885OPRK1 4651/4885MEN1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.